Get the Stockscreener App
3.84
0.52%
0.02
Genenta Science Spa Adr stock is traded at $3.84, with a volume of 354.
It is up +0.52% in the last 24 hours and up +1.05% over the past month.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
See More
Previous Close:
$3.82
Open:
$3.84
24h Volume:
354
Relative Volume:
0.03
Market Cap:
$70.23M
Revenue:
-
Net Income/Loss:
$-12.63M
P/E Ratio:
-5.5315
EPS:
-0.6942
Net Cash Flow:
$-12.18M
1W Performance:
-0.52%
1M Performance:
+1.05%
6M Performance:
-1.79%
1Y Performance:
-4.71%
1-Day Range:
$3.84
$3.84
1-Week Range:
$3.70
$3.96
52-Week Range:
$2.74
$7.28
Genenta Science Spa Adr Stock (GNTA) Company Profile
Name
Genenta Science Spa Adr
Sector
Industry
Phone
-
Address
-
Compare GNTA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GNTA
Genenta Science Spa Adr
|
3.84 | 70.34M | 0 | -12.63M | -12.18M | -0.6942 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.92 | 118.67B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.64 | 59.23B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
408.98 | 52.67B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
677.23 | 41.24B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
301.30 | 32.36B | 3.81B | -644.79M | -669.77M | -6.24 |
Genenta Science Spa Adr Stock (GNTA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-29-23 | Resumed | ROTH MKM | Buy |
| Jul-25-22 | Initiated | H.C. Wainwright | Buy |
| Jan-13-22 | Initiated | Maxim Group | Buy |
Genenta Science Spa Adr Stock (GNTA) Latest News
Applying sector rotation models to Altice USA Inc.Free Risk Managed Intraday Trade Alerts - Newser
Genenta Science S.p.A. to Terminate Dedicated Suite Agreement with AGC Biologics - MSN
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX) and Gilead Sciences (GILD) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Esperion (ESPR) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: NextCure (NXTC), Lexaria Bioscience (LEXX) and Travere Therapeutics (TVTX) - The Globe and Mail
Genenta Science stock maintains Buy rating as Temferon shows promise in GBM - Investing.com
Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar - GlobeNewswire Inc.
Genenta secures $21.9 million for cancer drug trial By Investing.com - Investing.com South Africa
Genenta secures €20M in mandatory convertible bond deal - Investing.com India
Genenta secures €20M in mandatory convertible bond deal By Investing.com - Investing.com South Africa
Genenta secures $21.9 million for cancer drug trial - Investing.com India
Genenta Science Secures €20 Million Convertible Bond Financing for Oncology Research - TipRanks
Genenta Science Secures €20 Million Financing to Boost Cancer Therapy Development - TipRanks
Oncology Breakthroughs: How Cancer Research Is Advancing in 202527.02.25News - Ariva
Genenta Science announces amendment to pact with AGC Biologics - Yahoo Finance
Genenta Science Enhances Manufacturing Agreement with AGC Biologics - TipRanks
Genenta Science Announces Shareholder Meeting - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
10 Best Italian Stocks To Buy Now - Yahoo Finance
Genenta Science Spa Adr Stock (GNTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.54%
0.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):